According to IMS Health, the global cancer market is on track to grow at a stellar CAGR of 13.7% over the next three years due to the advent of several game-changing therapies. While that’s an impressive growth rate for a drug market already valued in excess of $100 billion, it doesn’t mean that all, or even most, cancer stocks are screaming buys.